App Lauch & Donation to the Scott Carter Foundation for Childhood Cancer Research

Dear Friends & family,

We've launched a new iPhone & iPad app for Studio Frido called, FridoViewer. It is available on iTunes for $1.99.

I am asking for your help to get the word out about this this 3D science art app created in collaboration with computer scientist Jens Kruger.

We also have art collector quality prints available online.

If we can get 500 apps or prints sold between Nov 28 and Jan 2, we will donate $250 (or proportionally more, with no upper limit) to the Scott Carter Foundation in support of childhood cancer research. See also the Scott Carter collection of fine art prints here.

Thank you for supporting Studio Frido and Childhood Cancer research.

Charles

Studio FridoArt for the Science-Inspired Mind (SM)
http://www.studiofrido.com/

ps. we have 50 spare pairs of 3D glasses (these glasses are not at all required for the App, but useful for parts of it). Email me via charles (at) studiofrido.com with your postal mailing address and I’ll send you a pair of glasses.


about Studio Frido: Studio Frido is a collection of scientists who are passionate about the natural beauty in scientific research. 'Frido' is pediatric cancer researcher, Charles Keller.

about the Scott Carter Foundation: Scott Carter was a 13-year old boy who died in December of 1993 after a courageous three-year battle with bone cancer. Read more of Scott’s Story here. A major mission of the Scott Carter Foundation is to train the next generation of pediatric cancer researchers. Charles Keller was a recipient of a Scott Carter fellowship, and the Foundation has also sponsored cancer research trainees at the Oregon Health & Science University Pediatric Cancer Biology Program led by Dr. Keller.

about the Oregon Health & Science University Pediatric Cancer Biology Program: This program focuses the 1 in 5 children for whom survival is most a challenge from pediatric cancer. OHSU is a unique environment where non-chemotherapy, molecularly-targeted treatments were originally pioneered (i.e., Gleevec for the leukemia CML). The goal of the OHSU PCB is to create similarly effective and non-toxic therapies for the most challenging pediatric cancers.